Table 3.

Multivariable analysis of factors predicting progression-free and overall survival in patients with gBRCA1/2wt at CT initiation.

	PFS		OS
	HR [95% CI]	P	HR [95% CI]	P
Chemotherapy type (first line)
Non-platinum	1		1
Platinum	0.89 [0.71; 1.13]	0.339	0.97 [0.75; 1.25]	0.812
Age at MBC diagnosis
<50 years	1		1
≥50 years	1.00 [0.87; 1.15]	0.976	1.26 [1.07; 1.49]	0.006
Metastasis type
Visceral	1		1
Non-visceral	0.77 [0.66; 0.90]	0.001	0.72 [0.59; 0.87]	0.001
Number of metastatic sites (cl.)
<3 sites	1		1
≥3 sites	1.00 [0.84; 1.20]	0.984	1.07 [0.87; 1.32]	0.519
Breast cancer subtype*
HR+/HER2−	1		1
TNBC	1.52 [1.27; 1.83]	<0.001	2.20 [1.78; 2.70]	<0.001
Time from the primary tumour to MBC diagnosis
<6 months	1		1
6–24 months	1.94 [1.41; 2.67]	<0.001	2.37 [1.57; 3.58]	<0.001
>24 months	1.22 [0.91; 1.64]	0.18	1.30 [0.89; 1.92]	0.178
Time from MBC diagnosis to chemotherapy initiation
0–1 month	1		1
>1 month	0.99 [0.86; 1.15]	0.916	0.93 [0.78; 1.10]	0.373

gBRCA1/2wt germline BRCA1/2 wild-type, HER2− HER2 negative, HR+ hormone receptors positive, MBC metastatic breast cancer, PFS progression-free survival, OS overall survival, TNBC triple-negative breast cancer.

Bold values represent statistical significance p < 0.05.

*See definition of tumour subtype in “Methods”.